The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation

Abstract

Background

Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and STAMPEDE-Docetaxel studies demonstrated marked survival benefit with the addition of docetaxel to ADT in the mHSPC setting, leading to a change in the standard-of-care for mHSPC. The recent LATITUDE and STAMPEDE-Abiraterone trials showed similar substantial improvement in survival with the addition of abiraterone plus prednisone to ADT in this space.

Methods

We conducted a review of the randomized phase III studies that have investigated either the addition of docetaxel or abiraterone to ADT in patients with mHSPC.

Results

We describe the study designs, key eligibility criteria, and key results for the CHAARTED, STAMPEDE-Docetaxel, GETUG-AFU 15, LATITUDE, and STAMPEDE-Abiraterone clinical trials. We compare the data for abiraterone/prednisone plus ADT in mHSPC with the evidence for docetaxel plus ADT in these patients. Finally, we discuss several factors that should be considered when choosing between docetaxel/ADT or abiraterone/prednisone/ADT in mHSPC.

Conclusions

The management of mHSPC is evolving. Abiraterone plus prednisone in addition to ADT has emerged as an alternative standard-of-care to docetaxel plus ADT, and ongoing trials should clarify whether combination vs. sequential approaches with AR-targeting agents and taxane chemotherapy are preferred for initial management in the hormone-sensitive setting.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19:395–7.

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

    Article  PubMed  CAS  Google Scholar 

  3. 3.

    Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755–6.

    Article  PubMed  CAS  Google Scholar 

  4. 4.

    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  PubMed  CAS  Google Scholar 

  8. 8.

    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

    Article  PubMed  CAS  Google Scholar 

  9. 9.

    Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article  PubMed  CAS  Google Scholar 

  10. 10.

    Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537–47.

    Article  PubMed  Google Scholar 

  11. 11.

    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. 12.

    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. 13.

    Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377: 352–360.

    Article  PubMed  CAS  Google Scholar 

  14. 14.

    James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377: 388–351.

    Article  Google Scholar 

  15. 15.

    Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70:256–62.

    Article  PubMed  CAS  Google Scholar 

  16. 16.

    Stevens DJ, Sooriakumaran P. Oligometastatic prostate cancer. Curr Treat Options Oncol. 2016;17:62.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Sweeney CJ. Long term efficacy and QOL data of chemohormonal therapy in low and high volume hormone naive metastatic prostate cancer: E3805 CHAARTED trial. In: ESMO 2016 ABS 720PD. Milan Italy 2016.

  18. 18.

    James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028–38.

    Article  PubMed  Google Scholar 

  19. 19.

    Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984–90.

    Article  PubMed  Google Scholar 

  20. 20.

    Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164–9.

    Article  PubMed  CAS  Google Scholar 

  21. 21.

    Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68:325–34.

    Article  PubMed  Google Scholar 

  22. 22.

    Francini EGK, Xie W, Kantoff P, Harshman L, Tapllin ME, Sweeney C. Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database (abs 221). In: Genitourinary Cancers Symposium. Orlando FL 2017.

  23. 23.

    Gravis GBJ, Chen YH, Liu G, Fizazi K, Carducci M, Ooudard S, Joly F, Jarrard D, Soulie M, Eisenberger M, Habibian M, Dreicer R, Garcia J, Hussain M, Kohli M, Vogelzang N, Picus J, DiPaola R, Sweeney C. Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. In: Genitourinary Cancers Symposium. Orlando FL 2017;Abs 136.

  24. 24.

    Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.

    Article  PubMed  CAS  Google Scholar 

  25. 25.

    Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563–73.

    Article  PubMed  CAS  Google Scholar 

  26. 26.

    Miller RE, Sweeney CJ. Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:139–44.

    Article  PubMed  CAS  Google Scholar 

  27. 27.

    Tagawa STPE, Bruce JY, Lim EA, Petrylak DP, Peng W. Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32:abs 5025 is an abstract (ASCO, Chicago IL).

  28. 28.

    De Santis M, Saad F. Practical guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer. Urology. 2016;96:156–64.

    Article  PubMed  Google Scholar 

  29. 29.

    Pollard MM,AJ, Diefenbach MA, Hall SJ. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian J Urol. 2017;4:37–43.

    Article  PubMed  Google Scholar 

  30. 30.

    Hearn JW, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016;17:1435–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. 31.

    Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19:231–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. 32.

    Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. 33.

    Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014;5:5548.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

MM: Research funding to institution from Bayer, Janssen, Agensys, Seattle Genetics, Clovis, Astrazeneca. AJA: Research funding to institution from Bayer, Janssen, Medivation/Astellas/Pfizer, Dendreon, Sanofi Aventis, Gilead, Genentech/Roche, Novartis. Consulting with Janssen, Medivation/Pfizer/Astellas. Speaker for Bayer, Dendreon, Sanofi Aventis. CS: Research funding to institution from Astellas, Janssen, Sotio, Sanofi. Paid consultant to Astellas, Bayer, Genentech, Janssen, Pfizer, Sanofi. ESA: Paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, and ESSA. Research funding to institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, and Tokai. Co-inventor of a biomarker technology that has been licensed to Tokai and Qiagen.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Megan McNamara.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McNamara, M., Sweeney, C., Antonarakis, E.S. et al. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis 21, 306–318 (2018). https://doi.org/10.1038/s41391-017-0014-9

Download citation

Further reading

Search